Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587940 | 0.80 | OPRM1 (0.43) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL26723785 | 0.72 | HTR2A (0.47) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL699428 | 0.72 | CHRNA7 (0.50) | CYP2D6 | |
| SCHEMBL1348883 | 0.70 | HTR2A (0.58) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL3394400 | 0.68 | HTR2A (0.64) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL9425341 | 0.68 | TACR1 (0.46) | HTR2AHTR2CHTR7MRGPRX1CYP2D6 | |
| SCHEMBL31489727 | 0.67 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL3051979 | 0.67 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL26326631 | 0.66 | DHODH (0.54) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL9665371 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680421-B1 | USE OF TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-13 | — | — | EP | claimed |
| US-8513246-B2 | Use of N-heterocyclylmethylbenzamides in therapeutics | SANOFI (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20100022548-A1 | USE OF N-HETEROCYCLYLMETHYLBENZAMIDES IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-7619089-B2 | Derivatives of N-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20080070941-A1 | DERIVATIVES OF N-HETEROCYCLYLMETHYLBENZAMIDES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | US | disclosed |
| EP-1680421-B1 | USE OF TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-13 | — | — | EP | disclosed |
| US-7288656-B2 | Derivatives of N-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20060264441-A1 | Derivatives of N-heterocyclylmethylbenzamides, prepartion method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022548-A1 | USE OF N-HETEROCYCLYLMETHYLBENZAMIDES IN THERAPEUTICS | NMBR, EGLN2, KRAS | HTR2A 1304/4885HTR2C 1039/4885HTR7 2018/4885 |
| US-20080070941-A1 | DERIVATIVES OF N-HETEROCYCLYLMETHYLBENZAMIDES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | HNMT, CCKBR, CNR2 | HTR2A 1233/4885HTR2C 1535/4885HTR7 1670/4885 |
| US-20060264441-A1 | Derivatives of N-heterocyclylmethylbenzamides, prepartion method thereof and application of same in therapeutics | HNMT, CCKBR, CNR2 | HTR2A 1038/4885HTR2C 1180/4885HTR7 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.